Drug Search Results
More Filters [+]

GSK-2231392A

Alternative Names: GSK-2231392A, GSK2231392A, GSK 2231392A, GSK-2231392, GSK2231392, GSK 2231392
Latest Update: 2019-01-04
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Vaccine

Novel Mechanism: No

Modality: Vaccine

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for GSK-2231392A

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis B|Hepatitis A

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

NCT01777295

P2

Completed

Hepatitis A|Hepatitis B

2016-05-17

Recent News Events

Date

Type

Title